• Newsletter
  • Search
  • Contacto
  • Home (next newsletter)
  • Home
  • News # 80 | Jun. 2018
  • News # 81 | Jul. 2018
  • News # 82 | Set. 2018
  • News # 83 | Oct. 2018
  • News # 84 | Nov. 2018
  • News # 85 | Dec. 2018
  • News # 86 | Jan. 2019
  • News # 87 | Feb. 2019
  • News # 88 | Mar. 2019
  • News # 89 | Apr. 2019
  • News # 90 | May. 2019
  • News # 91 | Jun. 2019
  • News # 92 | Jul. 2019
  • News # 93 | sep. 2019
  • Newsletters
    • 2008 – 2009
      • News # 1 | nov. 2008
      • News # 10 | nov/dez. 2009
      • News # 2 | dec. 2008
      • News # 3 | jan/fev. 2009
      • News # 4 | mar. 2009
      • News # 5 | abr. 2009
      • News # 6 | mai/jun. 2009
      • News # 7 | jul. 2009
      • News # 8 | ago/set. 2009
      • News # 9 | out. 2009
    • 2010 – 2011
      • News # 11 | jan/fev. 2010
      • News # 12 | mar. 2010
      • News # 13 | abr. 2010
      • News # 14 | mai. 2010
      • News # 15 | jun/jul. 2010
      • News # 16 | ago/set. 2010
      • News # 17 | out/nov. 2010
      • News # 18 | dez. 2010
      • News # 19 | jan/fev. 2011
      • News # 20 | mar/abr. 2011
      • News # 21 | mai/jun. 2011
      • News # 22 | jul/ago. 2011
      • News # 23 | set/out. 2011
      • News # 24 | nov/dez. 2011
    • 2012 – 2013
      • News # 25 | jan. 2012
      • News # 26 | fev/mar. 2012
      • News # 27 | jun. 2012
      • News # 28 | ago. 2012
      • News # 29 | set/out. 2012
      • News # 30 | nov/dez. 2012
      • News # 31 | jan. 2013
      • News # 32 | mar. 2013
      • News # 33 | abr. 2013
      • News # 34 | mai. 2013
      • News # 35 | jun. 2013
      • News # 36 | set. 2013
      •  News # 37 | out. 2013
      • News # 38 | nov/dez. 2013
    • 2014 – 2015
      • News # 39 | jan/fev. 2014
      • News # 40 | mar. 2014
      • News # 41 | abr/mai. 2014
      • News # 42 | jun/jul. 2014
      • News # 43 | set. 2014
      • News # 44 | out/nov. 2014
      • News # 45 | dez. 2014
      • News # 46 | jan. 2015
      • News # 47 | fev. 2015
      • News # 48 | abr. 2015
      • News # 49 | mai. 2015
      • News # 50 | jun. 2015
      • News # 51 | set. 2015
      • News # 52 | out. 2015
      • News # 53 | dez. 2015
    • 2016 – 2017
      • News # 54 | jan. 2016
      • News # 55 | fev. 2016
      • News # 56 | mar. 2016
      • News # 57 | abr. 2016
      • News nº 58 | may 2016
      • News # 59 | jun. 2016
      • News # 60 | jul. 2016
      • News # 61 | set. 2016
      • News # 62 | out. 2016
      • News # 63 | nov/dez. 2016
      • News # 64 | jan. 2017
      • News # 65 | fev. 2017
      • News # 66 | mar. 2017
      • News # 67 | apr. 2017
      • News # 68 | may 2017
      • News # 69 | jun. 2017
      • News # 70 | jul. 2017
      • News # 71 | set. 2017
      • News # 72 | out. 2017
      • News # 73 | nov. 2017
      • News # 74 | dez. 2017
    • 2018
      • News # 75 | jan. 2018
      • News # 76 | fev. 2018
      • News # 77 | mar. 2018
      • News # 78 | abr. 2018
      • News #79 | May 2018
  • Subscribe Newsletter
My Company
  • Home
  • Newsletters
    • 2018 – 2019
      • News nº 92 | jul. 2019
      • News nº 91 | jun. 2019
      • News nº 90 | Mai. 2019
      • News nº 89 | Abr. 2019
      • News nº 88 | Mar. 2019
      • News nº 87 | Fev. 2019
      • News nº 86 | Jan. 2019
      • News nº 85 | Dez. 2018
      • News nº 84 | Nov. 2018
      • News nº 83 | Out. 2018
      • News nº 82 | Set. 2018
      • News nº 81 | Jul. 2018
      • News nº 80 | Jun. 2018
      • News Nº 79 | Mai. 2018
      • News nº 78 | abr. 2018
      • News nº 77 | mar. 2018
      • News nº 76 | fev. 2018
      • News nº 75 | jan. 2018
    • 2016 – 2017
      • News nº 74 | dez. 2017
      • News # 73 | nov. 2017
      • News # 72 | out. 2017
      • News # 70 | set. 2017
      • News nº 70 | jul. 2017
      • News nº 69 | jun. 2017
      • News nº 68 | mai. 2017
      • News nº 67 | abr. 2017
      • News nº 66 | mar. 2017
      • News nº 65 | fev. 2017
      • News nº 64 | jan. 2017
      • News nº 63 | nov/dez. 2016
      • News nº 62 | out. 2016
      • News nº 61 | set. 2016
      • News nº 60 | jul. 2016
      • News nº 59 | jun. 2016
      • News nº 58 | mai. 2016
      • News nº 57 | abr. 2016
      • News nº 56 | mar. 2016
      • News nº 55 | fev. 2016
      • News nº 54 | jan. 2016
    • 2014 – 2015
      • News nº 53 | dez. 2015
      • News nº 52 | out. 2015
      • News nº 51 | set. 2015
      • News nº 50 | jun. 2015
      • News nº 49 | mai. 2015
      • News nº 48 | abr. 2015
      • News nº 47 | fev. 2015
      • News nº 46 | jan. 2015
      • News nº 45 | dez. 2014
      • News nº 44 | out/nov. 2014
      • News nº 43 | set. 2014
      • News nº 42 | jun/jul. 2014
      • News nº 41 | abr/mai. 2014
      • News nº 40 | mar. 2014
      • News nº 39 | jan/fev. 2014
    • 2012 – 2013
      • News nº 38 | nov/dez. 2013
      • News nº 37 | out. 2013
      • News nº 36 | set. 2013
      • News nº 35 | jun. 2013
      • News nº 34 | mai. 2013
      • News nº 33 | abr. 2013
      • News nº 32 | mar. 2013
      • News nº 31 | jan. 2013
      • News nº 30 | nov/dez. 2012
      • News nº 29 | set/out. 2012
      • News nº 28 | ago. 2012
      • News nº 27 | jun. 2012
      • News nº 26 | fev/mar. 2012
      • News nº 25 | jan. 2012
    • 2010 – 2011
      • News nº 24 | nov/dez. 2011
      • News nº 23 | set/out. 2011
      • News nº 22 | jul/ago. 2011
      • News nº 21 | mai/jun. 2011
      • News nº 20 | mar/abr. 2011
      • News nº 19 | jan/fev. 2011
      • News nº 18 | dez. 2010
      • News nº 17 | out/nov. 2010
      • News nº 16 | ago/set. 2010
      • News nº 15 | jun/jul. 2010
      • News nº 14 | mai. 2010
      • News nº 13 | abr. 2010
      • News nº 12 | mar. 2010
      • News nº 11 | jan/fev. 2010
    • 2008 – 2009
      • News nº 10 | nov/dez. 2009
      • News nº 9 | out. 2009
      • News nº 8 | ago/set. 2009
      • News nº 7 | jul. 2009
      • News nº 6 | mai/jun. 2009
      • News nº 5 | abr. 2009
      • News nº 4 | mar. 2009
      • News nº 3 | jan/fev. 2009
      • News nº 2 | dez. 2008
      • News nº 1 | nov. 2008
  • Subscrever Newsletter
  • Contacto
Main Menu
  • Home
  • Newsletters
    • 2018 – 2019
      • News nº 92 | jul. 2019
      • News nº 91 | jun. 2019
      • News nº 90 | Mai. 2019
      • News nº 89 | Abr. 2019
      • News nº 88 | Mar. 2019
      • News nº 87 | Fev. 2019
      • News nº 86 | Jan. 2019
      • News nº 85 | Dez. 2018
      • News nº 84 | Nov. 2018
      • News nº 83 | Out. 2018
      • News nº 82 | Set. 2018
      • News nº 81 | Jul. 2018
      • News nº 80 | Jun. 2018
      • News Nº 79 | Mai. 2018
      • News nº 78 | abr. 2018
      • News nº 77 | mar. 2018
      • News nº 76 | fev. 2018
      • News nº 75 | jan. 2018
    • 2016 – 2017
      • News nº 74 | dez. 2017
      • News # 73 | nov. 2017
      • News # 72 | out. 2017
      • News # 70 | set. 2017
      • News nº 70 | jul. 2017
      • News nº 69 | jun. 2017
      • News nº 68 | mai. 2017
      • News nº 67 | abr. 2017
      • News nº 66 | mar. 2017
      • News nº 65 | fev. 2017
      • News nº 64 | jan. 2017
      • News nº 63 | nov/dez. 2016
      • News nº 62 | out. 2016
      • News nº 61 | set. 2016
      • News nº 60 | jul. 2016
      • News nº 59 | jun. 2016
      • News nº 58 | mai. 2016
      • News nº 57 | abr. 2016
      • News nº 56 | mar. 2016
      • News nº 55 | fev. 2016
      • News nº 54 | jan. 2016
    • 2014 – 2015
      • News nº 53 | dez. 2015
      • News nº 52 | out. 2015
      • News nº 51 | set. 2015
      • News nº 50 | jun. 2015
      • News nº 49 | mai. 2015
      • News nº 48 | abr. 2015
      • News nº 47 | fev. 2015
      • News nº 46 | jan. 2015
      • News nº 45 | dez. 2014
      • News nº 44 | out/nov. 2014
      • News nº 43 | set. 2014
      • News nº 42 | jun/jul. 2014
      • News nº 41 | abr/mai. 2014
      • News nº 40 | mar. 2014
      • News nº 39 | jan/fev. 2014
    • 2012 – 2013
      • News nº 38 | nov/dez. 2013
      • News nº 37 | out. 2013
      • News nº 36 | set. 2013
      • News nº 35 | jun. 2013
      • News nº 34 | mai. 2013
      • News nº 33 | abr. 2013
      • News nº 32 | mar. 2013
      • News nº 31 | jan. 2013
      • News nº 30 | nov/dez. 2012
      • News nº 29 | set/out. 2012
      • News nº 28 | ago. 2012
      • News nº 27 | jun. 2012
      • News nº 26 | fev/mar. 2012
      • News nº 25 | jan. 2012
    • 2010 – 2011
      • News nº 24 | nov/dez. 2011
      • News nº 23 | set/out. 2011
      • News nº 22 | jul/ago. 2011
      • News nº 21 | mai/jun. 2011
      • News nº 20 | mar/abr. 2011
      • News nº 19 | jan/fev. 2011
      • News nº 18 | dez. 2010
      • News nº 17 | out/nov. 2010
      • News nº 16 | ago/set. 2010
      • News nº 15 | jun/jul. 2010
      • News nº 14 | mai. 2010
      • News nº 13 | abr. 2010
      • News nº 12 | mar. 2010
      • News nº 11 | jan/fev. 2010
    • 2008 – 2009
      • News nº 10 | nov/dez. 2009
      • News nº 9 | out. 2009
      • News nº 8 | ago/set. 2009
      • News nº 7 | jul. 2009
      • News nº 6 | mai/jun. 2009
      • News nº 5 | abr. 2009
      • News nº 4 | mar. 2009
      • News nº 3 | jan/fev. 2009
      • News nº 2 | dez. 2008
      • News nº 1 | nov. 2008
  • Subscrever Newsletter
  • Contacto

Portuguese drug improves symptoms of Parkinson’s disease, under the coordination of Joaquim Ferreira.

By Ana Cristina Mota On 18 September, 2018 2018 | More and Better Comments Off on Portuguese drug improves symptoms of Parkinson’s disease, under the coordination of Joaquim Ferreira. No tags

A 100% Portuguese drug was created by Bial and is already on the market. The goal is to improve the symptoms of Parkinson’s disease.

Joaquim Ferreira, Professor at the Faculty of Medicine, Neurologist and Clinical Pharmacologist, played an important role in coordinating the clinical trials that led to the development of this drug.

Within the group of Movement disorders, Parkinson’s disease is identified by the tremor (clinical sign that most often leads people to the doctor) and slowing movements as a result of a dysfunction of the central nervous system. In a more serious state, it can cause a significant limitation in the patient’s mobility.

While knowing that there is a medication that can improve these symptoms is already excellent news, if this medicine has the intervention of a Faculty Professor, all the more proud this makes us.

We spoke to Professor Joaquim Ferreira to understand what it means to mitigate these effects of the disease.

“The problem with treating Parkinson’s disease is that we do not have a drug that stops the progression of the disease, or that makes it disappear. What happens with this disease is that, after a while, patients alternate periods in which they are blocked, do not move and are sitting on a chair without standing up and are unable to walk. It turns out that after taking the drug – LEVODOPA – they are agile and almost normal. This behaviour is called motor fluctuations: either they are off (turned off, don’t walk), or they’re on (move and walk). At this time, we are still very limited in decreasing the period of time in which patients are off. What this drug does is prolong the duration of the on stage, that is, prolong the time that they are well during the day. Patients taking part in this trial had about 6 to 7 hours of off daily and with the drug the overall reduction was about two hours, from six to four or four to two. That’s the gain; patients are more active.”

The only Portuguese laboratory to develop new drugs, Bial has a drug development programme, collaborating with people from the Faculty of Medicine in scientific areas that enrich pharmaceutical knowledge and expertise. “This is the right collaboration model between the university and the pharmaceutical industry and it is the ideal model. It happens here in Portugal, Israel and a few other countries. It is rare for the pharmaceutical industry to be open to these collaborations with the Academy.”

Bial also collaborates with the University of Porto’s Pharmacology Laboratory, which means that there is a true partnership between industry and academic departments.

“Without Bial, we would not have had the opportunity to actively participate in the development of a new drug. On the other hand, we have opened the doors of researchers and leading clinical and research centres in the area of Parkinson’s disease around the world for Bial”

How do you feel when you are part of a group that discovers and applies a drug that brings people more dignified conditions?

Joaquim Ferreira: It is really good.

I know notable researchers and clinicians who have spent a lifetime looking to contribute to a new treatment that makes a difference in patients’ lives.

But that said. it is important to reinforce that the drug was not developed by me, but by the Bial team, which is made up of highly qualified researchers, coordinated by Prof. Patrício Soares da Silva, who did a remarkable job, not only with this medication, but also with others. Our role was simply to help design the trials that contributed to generating the data needed for the drug to have reached this stage. But my role was to collaborate with Bial in a disease and scientific community that I know well. All of this gives us great satisfaction.”

 

nly now was the drug launched in Portugal, but it was approved two years ago, and is already sold in other countries. To finish up, and as Professor Joaquim Ferreira said, this drug and the bonds created between entities served “to break borders.”

Perhaps one day, we will be able to attenuate the disease so drastically that it is cured the way an antibiotic treats an infection.

On 5th September the Rádio e Televisão de Portugal ran a story about this medication. You can review this report here (image credits RTP).

Joana Sousa

Editorial Team

Share

Search

Índice – News nº 82 | set. 2018
 Editorial Note
 Faculty of Medicine Day
 Official opening of the degree in Nutrition Sciences
 The method and accuracy of Joaquim Ferreira
 Andreia Daniel – President of the AEFML
 30 years after José Pinto Correia’s departure
 New MIM Students Code of Honour Ceremony
 Portuguese drug improves symptoms of Parkinson’s disease, under the coordination of Joaquim Ferreira.
 Projetando a FMUL: O impacto da Afiliação Institucional
 Publons Peer Review Award for Professor Mamede de Carvalho
 The first day at the Faculty
 Cursos do GAPIC – Um suporte à prática de investigação
 A Marta e a Mariana contam-nos o que é o Projeto Medicina Mais Perto: Moçambique.
 Tópicos em destaque… VIH – Inibidores da Integrase
 SummerSchool on Clinical Knowledge in the Development of New Medical Devices
 This school year, follow us!
 Publicações Científicas (FMUL/HSM/IMM) julho – setembro 2018
 Ana Abreu, a Cardiologista que promete revolucionar os hábitos dos doentes cardíacos
 FMUL and Universidade Federal do Rio de Janeiro (UFRJ) reinforce the umbilical connection
 Clara Pinto Correia: Just the two of us And the Benzene ring
 Margarida Pinto Correia: The long way to Tipperary
 Physicians, Innovation and Responsibility – Facts and Lessons of an Exemplary Story
 The Choir and Orchestra of the Faculty of Medicine
 World Heart Day | A Healthy Heart | SEPT 28-29
 Research needs YOU! – GAPIC Competition 2018
 Concerto Solidário – Amigas do Peito
 José Manuel Vieira Barbas (1944-2018)
 Helena Lopes da Silva (1949-2018)
My Company

100 AnosPropriedade e Edição: Faculdade de Medicina da Universidade de Lisboa NIPC: 502662875  Periodicidade: Mensal  Diretor: Prof. Doutor Fausto J. Pinto Conselho Editorial: Prof. Doutor Fausto J. Pinto, Profª. Doutora Ana Sebastião, Prof. Doutor Mamede de Carvalho, Prof. Doutor António Vaz Carneiro, Prof. Doutor Miguel Castanho, Dr. Luís Pereira  Equipa Editorial:  Ana Raquel Moreira, Cristina Bastos, Isabel Varela, Joana Sousa, Maria de Lurdes Barata, Rui Gomes, Sónia Teixeira  Colaboração:  Gabinete de Relações Públicas, Internacionais e Comunicação  Versão Inglesa: AP|PORTUGAL- Language Services  Conceção: Metatexto, Lda. e-mail: news@medicina.ulisboa.pt  Sede do Editor e Sede da Redação: Avenida Prof. Egas Moniz, 1649-028 Lisboa Estatuto Editorial Anotado na ERC 

  • Increase Font
  • Decrease Font
  • Black & White
  • Inverse Colors
  • Highlight Links
  • Regular Font
  • Reset
Real Accessability